HOMEVULNERABILITIESCVE-2026-32921
MEDIUM

CVE-2026-32921

CWE-367Published: March 31, 2026· Updated: Apr 2, 2026

5.0
CVSS v3.1
EPSS:0.05%probability of exploitation in 30 daysPercentile:14.9th

Official Description

OpenClaw before 2026.3.8 contains an approval bypass vulnerability in system.run where mutable script operands are not bound across approval and execution phases. Attackers can obtain approval for script execution, modify the approved script file before execution, and execute different content while maintaining the same approved command shape.

NVD Source

Technical Analysis

CVE-2026-32921 can be exploited remotely over the network without requiring physical or adjacent access, significantly expanding the attack surface for threat actors.

Exploitation requires low privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorNetwork
Attack ComplexityHigh
Privileges Req.Low
User InteractionNone
ScopeUnchanged
Impact
ConfidentialityLow
IntegrityLow
AvailabilityLow
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:L/A:L

Affected Vendors & Products

openclaw1 product
openclaw
Source: NVD CPE · 1 total CPE entries

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (4)

Quick Facts

CVE IDCVE-2026-32921
CVSS Score5.0 / 10
SeverityMEDIUM
WeaknessCWE-367
CISA KEVNo
EPSS (30d)0.05%
Affected1 vendor
PublishedMar 31, 2026

Related CVEs (CWE-367)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2026-32921 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.